Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026

Key Takeaways

• Cytokinetics will announce pivotal Phase 3 ACACIA-HCM trial results for aficamten in non-obstructive hypertrophic cardiomyopathy on May 5, 2026
• The trial could establish aficamten as a potential first-in-class treatment for patients with limited therapeutic options
• Company will host investor conference call at 8:00 AM ET to discuss clinical data and regulatory pathway

---

Cytokinetics, Incorporated (Nasdaq: CYTK) announced it will report topline results from its pivotal Phase 3 clinical trial ACACIA-HCM on Tuesday, May 5, 2026, evaluating aficamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM).

The South San Francisco-based biotechnology company will host a conference call at 8:00 AM Eastern Time following the data announcement to discuss the results with investors and analysts.

About the ACACIA-HCM Trial

The ACACIA-HCM study (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) represents a critical milestone for Cytokinetics’ cardiac muscle program. The randomized, placebo-controlled trial evaluates aficamten’s efficacy and safety in treating patients with non-obstructive hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy affects approximately 1 in 500 people worldwide, making it one of the most common inherited heart conditions. The non-obstructive form presents unique treatment challenges, as patients experience symptoms without the left ventricular outflow tract obstruction seen in obstructive HCM.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Treatment Landscape

Aficamten, a next-generation cardiac myosin inhibitor, could potentially address significant unmet medical needs in the HCM patient population. Current treatment options for non-obstructive HCM remain limited, primarily focusing on symptom management rather than targeting the underlying disease mechanism.

The upcoming results could position Cytokinetics to compete in the expanding HCM therapeutics market, particularly following the recent regulatory approvals of other cardiac myosin inhibitors for obstructive HCM.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

What’s Next

Positive trial results could support regulatory submissions to the FDA and international health authorities. The company’s investor call will likely provide insights into the regulatory timeline and commercial strategy for aficamten in the non-obstructive HCM indication.

---

Frequently Asked Questions

What is non-obstructive hypertrophic cardiomyopathy?

Non-obstructive HCM is a genetic heart condition where the heart muscle thickens without blocking blood flow out of the heart, unlike obstructive HCM. Patients still experience symptoms like shortness of breath and fatigue but have limited treatment options.

When could aficamten become available for patients?

If the Phase 3 trial results are positive, Cytokinetics would need to submit regulatory applications and receive approval from the FDA and other agencies. This process typically takes 6-12 months after submission, meaning potential availability in 2027 at the earliest.

How does aficamten work differently from existing treatments?

Aficamten is a cardiac myosin inhibitor that directly targets the underlying mechanism of HCM by reducing excessive heart muscle contraction. This differs from current treatments that primarily manage symptoms rather than address the root cause of the disease.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update